scAAV CMV-GFP (30 µl)

scAAV(BR1)-GFP is a pre-packaged self-complementary AAV (scAAV) in serotype BR1 (with capsid from serotype BR1 and 2xITR from serotype 2) which will over-express EGFP under CMV promoter. Ready to use format.

AAV serotype BR1, a newly identified serotype from capsid AAV2 mutant has shown excellent transduction efficiency for neurovascular (blood–brain barrier‐associated) endothelial cells in vivo and in vitro. AAV‐BR1 can be used to ameliorate the severe neurological impairments in a mouse model of incontinentia pigmenti.